



Claire Cassedy <clairepcassedy@gmail.com>

KEI Comments Re: Prospective Grant of Exclusive Patent License: Chimeric Antigen Receptors Targeting CD56 (86 FR 16602)

Freel, Rose (NIH/NCI) [E] <rose.freel@nih.gov>

Thu, Apr 15, 2021 at 2:05 PM

To: Claire Cassedy <claire.cassedy@keionline.org>

Cc: James Love <james.love@keionline.org>

Dear Ms. Cassedy,

Thank you for your comments dated April 14, 2021 on the Prospective Grant of an Exclusive License to Memorial Sloan Kettering Cancer Center (MSKCC) for our co-owned invention related to Chimeric Antigen Receptors Targeting CD56. As you've noted in your comments, the purpose of this proposed exclusive license is to consolidate rights with MSKCC to allow them to take the lead in licensing the technology for commercial development.

Your recommendations regarding specific terms to be added to the license with MSKCC have been reviewed and noted. It's worth noting that the majority of the comments you provided have been previously addressed by the NIH on other prospective licenses.

Best Regards,

Rose Freel

--

Rose Santangelo Freel, Ph.D.

Senior Technology Transfer Manager

National Cancer Institute

P 301-624-1257 | rose.freel@nih.gov

From: Claire Cassedy <claire.cassedy@keionline.org>

Sent: Wednesday, April 14, 2021 9:07 PM

To: Freel, Rose (NIH/NCI) [E] <rose.freel@nih.gov>

Cc: James Love <james.love@keionline.org>

[Quoted text hidden]

[Quoted text hidden]